Cancer origin determination combined with site-specific treatment of metastatic cancer 23 patients is critical to improve patient outcomes. Existing pathology and gene expression-based 24 techniques often have limited performance. In this study, we developed a deep neural network 25 (DNN)-based classifier for cancer origin prediction using DNA methylation data of 7,339 patients of 26 18 different cancer origins from The Cancer Genome Atlas (TCGA). This DNN model was 27 evaluated using four strategies: (1) when evaluated by 10-fold cross-validation, it achieved an 28 overall specificity of 99.72% (95% CI 99.69%-99.75%) and sensitivity of 92.59% (95% CI 91.87%-29 93.30%); (2) when tested on hold-out testing data of 1,468 patients, the model had an overall 30 specificity of 99.83% and sensitivity of 95.95%; (3) when tested on 143 metastasized cancer patients 31 (12 cancer origins), the model achieved an overall specificity of 99.47% and sensitivity of 95.95%; 32 and (4) when tested on an independent dataset of 581 samples (10 cancer origins), the model 33 achieved overall specificity of 99.91% and sensitivity of 93.43%. Compared to existing pathology 34 and gene expression-based techniques, the DNA methylation-based DNN classifier showed higher 35 performance and had the unique advantage of easy implementation in clinical settings. 36 37 38 39 40 41 42 43 44
Introduction 46
Identification of cancer origins is routinely performed in clinical practice as site-specific 47 treatments improve patient outcomes [1] [2] [3] [4] . While some cancer origins are easy to be determined, others 48 are difficult, especially for metastatic and un-differentiated cancer. Cancer origin determination is 49 typically carried out with immunohistochemistry panels on the tumor specimen and imaging tests, which 50 need considerable resources, time, and expense. In addition, pathologic-based procedures have limited 51 accuracy (66-88%) in determining the origins of metastatic cancer [5] [6] [7] [8] .
52 Several gene expression-or microRNA-based molecular classifiers have been developed to 53 identify cancer origin. A k-nearest neighbor classifier based on 92 genes showed an accuracy of 84% in 54 identifying primary site of metastatic cancer via cross-validation [9] . Pathwork, a commercially available 55 platform based on similarity score of 1,550 genes between cancer tissue and reference tissue, achieved an 56 overall sensitivity of 88%, an overall specificity of 99% and an accuracy of 89% in identifying tissue of 57 origin [10, 11] . A decision-tree classifier based on 48 microRNA showed an accuracy of 85-89% in 58 identification of cancer primary sites [12, 13] , and an updated version, the 64-microRNA based assay, 59 exhibited an overall sensitivity of 85% [14, 15] . A recent support vector machine-based classifier that 60 integrated gene expression and histopathology showed an accuracy of 88% in known origins of cancer 61 samples [16] . All these molecular platforms have shown better performance in identifying tissue of origin 62 as compared to pathology-based methods. However, gene expression-or microRNA-bases classifiers 63 need to handle RNA that is unstable and less convenient in clinic settings. In addition, these classifiers 64 have performance of <90% accuracy, which may further limit their wide adoption in clinical settings.
65
Hence, it is desirable to develop higher performance prediction tools for cancer origin determination,
66
which can also be easily implemented in clinical settings.
67
DNA methylation is a process by which methyl groups are added to the DNA molecule and 70-
68
80% of human genome is methylated [17] . It has been shown that DNA methylation is established in tissue specific manner during development [18, 19] . Though the genomes of cancer patients exhibit overall demethylation, tissue specific DNA methylation markers might be conserved [19] . Indeed, a 71 random forest-based cancer origin classifier using DNA methylation was reported to achieve a In order to evaluate the classifier trained on TCGA dataset using independent data, we obtained 99 11 DNA methylation datasets (Illumina 450k platform) from Gene Expression Omnibus (GEO) [31] 100 using GEOquery (Bioconductor package, version 2.42.0) [32] . A total of 581 cancer patients covering 10 101 cancer origins were obtained and the information for each dataset was described in Table 1 . 
Results

152
The overall performance of the DNN-based cancer origin classifier 153 in 10-fold cross-validation setting 154 We used DNA methylation data of 7,339 patients from TCGA across 18 primary tissues to train and test a DNN-based cancer origin classifier. The sample distribution in different cancer origins were shown in Fig 1. The final DNN architecture consists of one input layer (10,360 neurons), two hidden 157 layers (64 neurons each layer) and one output layer (18 neurons) that represents 18 cancer origins (Fig 2) . 
DNN-based cancer origin classifier shows high performance in
171 testing dataset 172 We tested the classifier using test dataset, which includes 1,468 samples with similar distribution 173 with training set (Fig 1) . Cancer origin classification and a confusion matrix for all samples were shown 174 in S1 and S2 Tables respectively. Model performance metrics were shown on Table 3 . The specificity and 175 negative predictive value (NPV) in individual cancer origin prediction were consistently higher than 0.99.
176
The overall precision (PPV) and recall (sensitivity) reached 0.9608 and 0.9595 respectively. For many 177 cancer tissue origin predictions, including brain, colorectal, prostate, skin, testis, thymus and thyroid, this 
185
There are some variations in precision and recall in different cancer origin predictions. The 186 lowest performance occurred in esophagus origin prediction with a precision of 0.7579 and a recall of 187 0.7410. A total of 10 of 39 esophagus origins were incorrectly predicted as stomach origins (S1 and S2
188
Tables). Given that esophagus is a broad area, if a tumor is located at the border of stomach and 189 esophagus, it might be difficult for the classifier to distinguish these two tissues. In addition, tissues from 190 adjacent regions may have similar methylation profiles so that the methylation-based prediction model 191 has difficulty in differentiating cancers with adjacent origins (e.g., esophagus vs stomach).
192
DNN-based cancer tissue classifier shows high performance in
194 determining the origins of metastasized cancers 195 We evaluated the performance of the classifier in determining the origins of metastatic cancers 196 that nested in our test data. Our data contained 701 samples from distantly metastasized cancers and 558 197 of them have been used for model development. We then used remaining 143 samples from 12 cancer 198 origins with various sample sizes for evaluation ( Fig 4A) . Cancer origin predictions and corresponding 199 confusion matrix were shown in S3 and S4 Tables. Model performance metrics and ROC curves were 200 shown in Table 4 and Fig 4B. Consistently, DNN model showed robust high performance in predicting 201 metastatic cancer origins. Note: PPV: positive predictive value; NPV: negative predictive value.
209
of 0.22 for esophagus origin prediction, a precision of 0.67 for liver origin prediction and a recall of 0.67 210 for lung prediction. The poor performance in these three cancer origin predictions may be due to small 211 sample size. As mentioned above, metastatic cancer samples comprise only a small subset of test dataset 212 in TCGA, the majority of which are primary tumors. Only 2, 2 and 3 metastatic cancer samples from 213 esophagus, liver and lung origin respectively were included in test dataset ( Fig 4A) . The classifier mis-214 classified 6 out of 60 head and neck cancers as esophagus origin and 1 of 3 of lung cancers as liver 215 cancers (S4 Table) . Due to small sample sizes for esophagus, liver and lung cancers, a few mis-216 classifications had significant impacts on the precision metrics.
218
DNN-based cancer tissue classifier shows high performance in
219 independent testing datasets 220
The DNN model was trained using DNA methylation data from TCGA. We then tested it in 221 independent datasets of 11 data series consisting of 581 tumor samples covering 10 tissue origins 222 downloaded from Gene Expression Omnibus (GEO). The sample distribution was shown in Fig 5A and 223 cancer origin predictions were listed in S5 Table. Evaluated using these independent datasets, the DNN 224 model achieved high performance with an overall precision and recall of 98.69% and 93.43% respectively 225 (Table 5) . High performance was also achieved in individual cancer origin predictions (Table 5) with an 226 average AUC of 0.99 ( Fig 5B) . Importantly, the model achieved 100% accuracy in predicting the origins 227 of metastatic cancers in these datasets, including 24 prostate cancer that metastasized to bone, lymph node 228 or soft tissue and 12 breast cancer that metastasized to lymph node (see Table 1 for these samples). 
257
Our DNN model has potential in predicting origins of Cancer of Unknown Primary origin (CUP).
258
CUP is a sub-group of heterogenous metastatic cancer with illusive primary site even after standard 259 pathological examination [38] . It is estimated that 3-5% metastatic cancers are CUP and the majority of 
264
However, due to the limited CUP data in both TCGA and GEO, we currently are unable to test the DNN 265 models in predicting the origins of CUP. Our future direction is to collaborate with hospital to collect 266 DNA methylation data from CUP patients to test our model. One challenge is to obtain the true primary 267 sites for these patients. Due to unknown property of CUP, true primary sites may be established in later 268 cancer development [20] . Another is through the post-mortem examination of patients since 75% of 269 primary sites of CUP were found in autopsy [41].
270
One limitation of this study is that small sizes of metastatic cancers in our data. 
